

ASX RELEASE

23 August 2024

Results of Annual General Meeting

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to confirm that each of the resolutions put to its Annual General Meeting held earlier today were carried.

Details of the results of the meeting are attached.

This ASX announcement is authorised for release by the Company Secretary.

- End -

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [Twitter](#) (@ampliatx), [Threads](#) (@ampliatx) and [LinkedIn](#).

AMPLIA THERAPEUTICS LIMITED

Annual General Meeting

Friday, 23 August 2024

Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Remuneration Report	Ordinary	109,717,380 96.11%	140,700 0.12%	4,300,629 3.77%	88,682	114,293,754 99.88%	140,700 0.12%	88,682	Carried
2 Re-elect Dr Robert Peach as a Director of the Company	Ordinary	118,817,223 96.48%	32,920 0.03%	4,300,629 3.49%	4,476,033	123,393,597 99.97%	32,920 0.03%	4,476,033	Carried
3 Re-elect Ms Jane Bell as a Director of the Company	Ordinary	123,237,676 96.63%	4,500 0.00%	4,300,629 3.37%	84,000	127,814,050 100.00%	4,500 0.00%	84,000	Carried
4 Proposed Issue of Shares to Dr Christopher Burns (Managing Director and Chief Executive Officer)	Ordinary	109,608,229 96.00%	258,733 0.23%	4,300,629 3.77%	9,067,181	114,184,603 99.77%	258,733 0.23%	9,067,181	Carried
5 Ratify the Previous Issue of 3,500,000 Options	Ordinary	104,115,506 95.90%	155,520 0.14%	4,300,629 3.96%	19,055,150	108,691,880 99.86%	155,520 0.14%	19,055,150	Carried
6 Approval for extra 10% Placement Facility	Special	104,525,176 82.01%	18,637,150 14.62%	4,300,629 3.37%	163,850	109,101,550 85.41%	18,637,150 14.59%	163,850	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.